CA2192678A1 - Mn gene and protein - Google Patents
Mn gene and proteinInfo
- Publication number
- CA2192678A1 CA2192678A1 CA002192678A CA2192678A CA2192678A1 CA 2192678 A1 CA2192678 A1 CA 2192678A1 CA 002192678 A CA002192678 A CA 002192678A CA 2192678 A CA2192678 A CA 2192678A CA 2192678 A1 CA2192678 A1 CA 2192678A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- nucleic acid
- protein
- exclusive
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract 32
- 102000004169 proteins and genes Human genes 0.000 title claims abstract 24
- 150000007523 nucleic acids Chemical class 0.000 claims abstract 28
- 108020004707 nucleic acids Proteins 0.000 claims abstract 21
- 102000039446 nucleic acids Human genes 0.000 claims abstract 21
- 229920001184 polypeptide Polymers 0.000 claims abstract 21
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 21
- 238000000034 method Methods 0.000 claims abstract 11
- 230000014509 gene expression Effects 0.000 claims abstract 8
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims abstract 7
- 201000010099 disease Diseases 0.000 claims abstract 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 7
- 230000002068 genetic effect Effects 0.000 claims abstract 7
- 230000001613 neoplastic effect Effects 0.000 claims abstract 6
- 238000003752 polymerase chain reaction Methods 0.000 claims abstract 5
- 239000000427 antigen Substances 0.000 claims abstract 4
- 102000036639 antigens Human genes 0.000 claims abstract 4
- 108091007433 antigens Proteins 0.000 claims abstract 4
- 230000001855 preneoplastic effect Effects 0.000 claims abstract 3
- 230000000692 anti-sense effect Effects 0.000 claims abstract 2
- 238000003384 imaging method Methods 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims abstract 2
- 229960005486 vaccine Drugs 0.000 claims abstract 2
- 239000002773 nucleotide Substances 0.000 claims 24
- 125000003729 nucleotide group Chemical group 0.000 claims 24
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 20
- 102000037865 fusion proteins Human genes 0.000 claims 11
- 108020001507 fusion proteins Proteins 0.000 claims 11
- 230000000295 complement effect Effects 0.000 claims 10
- 210000004408 hybridoma Anatomy 0.000 claims 5
- 239000013598 vector Substances 0.000 claims 5
- 108020004705 Codon Proteins 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 238000009396 hybridization Methods 0.000 claims 3
- 231100000167 toxic agent Toxicity 0.000 claims 3
- 239000003440 toxic substance Substances 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000012216 imaging agent Substances 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 239000013612 plasmid Substances 0.000 claims 2
- 108700024394 Exon Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000002357 endometrial effect Effects 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 claims 1
- 238000003149 assay kit Methods 0.000 abstract 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 abstract 1
- 108700020796 Oncogene Proteins 0.000 abstract 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 238000001261 affinity purification Methods 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 239000002299 complementary DNA Substances 0.000 abstract 1
- 238000003018 immunoassay Methods 0.000 abstract 1
- -1 is disclosed Proteins 0.000 abstract 1
- 239000002853 nucleic acid probe Substances 0.000 abstract 1
- 230000008707 rearrangement Effects 0.000 abstract 1
- 239000000523 sample Substances 0.000 abstract 1
- 108700026220 vif Genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pregnancy & Childbirth (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
A complete genomic sequence including a full-length cDNA sequence for the MN
gene, a putative oncogene, is disclosed, as well as proteins/polypeptides encoded thereby Recombinant nucleic acid molecules for expressing MN proteins/polypeptides and recombinant proteins are also provided. Expression of the MN gene is disclosed as being associated with tumorigenicity, and the invention concerns methods and compositions for detecting and/or quantitating MN antigen and/or MN-specific antibodies in vertebrate samples that are diagnostic/prognostic for neoplastic and preneoplastic disease. Test kits embodying the immunoassays of this invention are provided, MN-specific antibodies are disclosed that can be used diagnostically/prognostically, therapeutically, for imaging, and/or for affinity purification of MN proteins/polypeptides. Also provided are nucleic acid probes for the MN
gene as well as test kits comprising said probes The invention also concerns vaccines comprising MN proteins/polypeptides which are effective to immunize a vertebrate against neoplastic diseases associated with the expression of MN proteins. The invention still further concerns antisense nucleic acid sequences that can be used to inhibit MN gene expression, and polymerase chain reaction (PCR) assays to detect genetic rearrangements in MN genes.
gene, a putative oncogene, is disclosed, as well as proteins/polypeptides encoded thereby Recombinant nucleic acid molecules for expressing MN proteins/polypeptides and recombinant proteins are also provided. Expression of the MN gene is disclosed as being associated with tumorigenicity, and the invention concerns methods and compositions for detecting and/or quantitating MN antigen and/or MN-specific antibodies in vertebrate samples that are diagnostic/prognostic for neoplastic and preneoplastic disease. Test kits embodying the immunoassays of this invention are provided, MN-specific antibodies are disclosed that can be used diagnostically/prognostically, therapeutically, for imaging, and/or for affinity purification of MN proteins/polypeptides. Also provided are nucleic acid probes for the MN
gene as well as test kits comprising said probes The invention also concerns vaccines comprising MN proteins/polypeptides which are effective to immunize a vertebrate against neoplastic diseases associated with the expression of MN proteins. The invention still further concerns antisense nucleic acid sequences that can be used to inhibit MN gene expression, and polymerase chain reaction (PCR) assays to detect genetic rearrangements in MN genes.
Claims (28)
1. An isolated nucleic acid containing at least twenty-seven nucleotides wherein the nucleotide sequence for said nucleic acid is selected from the group consisting of:
(a) SEQ. ID. NOS.: 1, 5, 27, 28, 30-33, and 38, and nucleotide sequences complementary to SEQ. ID. NOS.: 1, 5, 27, 28, 30-33 and 38.
(b) nucleotide sequences that hybridize under stringent hybridization conditions to: SEQ. ID. NO.: 5 exclusive of the nucleotide sequence from 3660 to 3951 and exclusive of the exon sequences represented by SEQ. ID. NOS.: 29-38, or to the complement of SEQ. ID.
NO.: 5 exclusive of said nucleotide sequence from 3660 to 3951 and exclusive of said exon sequences repesented by SEQ. ID. NOS.: 29-38: and (c) nucleotide sequences that differ from the nucleotide sequences of (a) and (b) in codon sequence due to the degeneracy of the genetic code.
(a) SEQ. ID. NOS.: 1, 5, 27, 28, 30-33, and 38, and nucleotide sequences complementary to SEQ. ID. NOS.: 1, 5, 27, 28, 30-33 and 38.
(b) nucleotide sequences that hybridize under stringent hybridization conditions to: SEQ. ID. NO.: 5 exclusive of the nucleotide sequence from 3660 to 3951 and exclusive of the exon sequences represented by SEQ. ID. NOS.: 29-38, or to the complement of SEQ. ID.
NO.: 5 exclusive of said nucleotide sequence from 3660 to 3951 and exclusive of said exon sequences repesented by SEQ. ID. NOS.: 29-38: and (c) nucleotide sequences that differ from the nucleotide sequences of (a) and (b) in codon sequence due to the degeneracy of the genetic code.
2. An isolated nucleic acid according to Claim 1 wherein said nucleotide sequence is selected from the group consisting of:
(a) SEQ. ID. NO.: 5 and its complement;
(b) nucleotide sequences that hybridize under stringent conditions to SEQ. ID. NO.: 5 exclusive of the nucleotide sequence from 3660 to 3951 and exclusive of the exon sequences represented by SEQ. ID.
NOS.: 29-38 or to the complement of SEQ. ID. NO.: 5 exclusive of said nucleotide sequence from 3660 to 3951 and exclusive of said exon sequences represented by SEQ. ID. NOS.: 29-38;
(c) nucleotide sequences that differ from the nucleotide sequences of (a) or (b) in codon sequence due to the degeneracy of the genetic code.
(a) SEQ. ID. NO.: 5 and its complement;
(b) nucleotide sequences that hybridize under stringent conditions to SEQ. ID. NO.: 5 exclusive of the nucleotide sequence from 3660 to 3951 and exclusive of the exon sequences represented by SEQ. ID.
NOS.: 29-38 or to the complement of SEQ. ID. NO.: 5 exclusive of said nucleotide sequence from 3660 to 3951 and exclusive of said exon sequences represented by SEQ. ID. NOS.: 29-38;
(c) nucleotide sequences that differ from the nucleotide sequences of (a) or (b) in codon sequence due to the degeneracy of the genetic code.
3. An isolated nucleic acid containing at least sixteen nucleotides wherein the nucleotide sequence therefor is selected from the group consisting of:
(a) the MN nucleotide sequences contained in plasmids A4a, XE1 and XE3 which were deposited at the American Type Culture Collection (ATCC) in Rockville, Maryland in the United State of America under the respective ATCC Nos. 97199, 97200, and 97198;
(b) nucleotide sequences that hybridize under stringent conditions to the MN nucleotide sequences of (a) with the proviso that excluded from said MN nucleotide sequences of (a) are the nucleotide sequence from 3660 to 3951 of SEQ. ID. NO.: 5 and MN exon sequences represented by SEQ. ID. NOS.: 29-38; and (c) nucleotide sequences that differ from the nucleotide sequences of (a) or (b) in codon sequence due to the degeneracy of the genetic code.
(a) the MN nucleotide sequences contained in plasmids A4a, XE1 and XE3 which were deposited at the American Type Culture Collection (ATCC) in Rockville, Maryland in the United State of America under the respective ATCC Nos. 97199, 97200, and 97198;
(b) nucleotide sequences that hybridize under stringent conditions to the MN nucleotide sequences of (a) with the proviso that excluded from said MN nucleotide sequences of (a) are the nucleotide sequence from 3660 to 3951 of SEQ. ID. NO.: 5 and MN exon sequences represented by SEQ. ID. NOS.: 29-38; and (c) nucleotide sequences that differ from the nucleotide sequences of (a) or (b) in codon sequence due to the degeneracy of the genetic code.
4. An isolated nucleic acid according to Claim 3 which functions as a polymerase chain reaction primer for MN nucleic acid sequences, and which is from 16 to about 50 nucleotides in length.
5. An isolated nucleic acid, containing at least fifty nucleotides, encoding an MN protein or polypeptide that is specifically bound either by monoclonal antibodies designated M75 secreted by the hybridoma VU-M75 deposited at the American Type Culture Collection (ATCC) in Rockville, Maryland in the United States of America under ATCC
No. HB 11128, or by monoclonal antibodies designated MN12 secreted by the hybridoma MN 12.2.2 deposited at the ATCC under ATCC No. 11647, or by both of said monoclonal antibodies.
No. HB 11128, or by monoclonal antibodies designated MN12 secreted by the hybridoma MN 12.2.2 deposited at the ATCC under ATCC No. 11647, or by both of said monoclonal antibodies.
6. An isolated nucleic acid which is operatively linked to an expression control sequence within a vector wherein said nucleic acid is selected from the group consisting of:
(a) SEQ. ID. NO.: 1 and its complement;
(b) nucleic acids that hybridize under stringent hybridization conditions to SEQ. ID. NO.: 1 exclusive of the nucleotide sequence from 124 to 1522, or to the complement of SEQ. ID. NO.: 1 exclusive of said nucleotide sequence from 124 to 1522;and (c) nucleic acids that differ from the nucleic acid sequences of (a) and (b) due to the degeneracy of the genetic code.
(a) SEQ. ID. NO.: 1 and its complement;
(b) nucleic acids that hybridize under stringent hybridization conditions to SEQ. ID. NO.: 1 exclusive of the nucleotide sequence from 124 to 1522, or to the complement of SEQ. ID. NO.: 1 exclusive of said nucleotide sequence from 124 to 1522;and (c) nucleic acids that differ from the nucleic acid sequences of (a) and (b) due to the degeneracy of the genetic code.
7. A unicellular host, which is either prokaryotic or eukaryotic, that is transformed or transfected with the isolated nucleic acid operatively linked to an expression control sequence in a vector according to Claim 6.
8. A method of recombinantly producing an MN protein, MN fusion protein or MN polypeptide comprising the steps of:
(a) transforming a unicellular host with the isolated nucleic acid operatively linked to an expression control sequence in a vector according to Claim 6;
(b) culturing said unicellular host so that said MN protein or polypeptide is expressed; and (c) extracting and isolating said MN protein or polypeptide.
(a) transforming a unicellular host with the isolated nucleic acid operatively linked to an expression control sequence in a vector according to Claim 6;
(b) culturing said unicellular host so that said MN protein or polypeptide is expressed; and (c) extracting and isolating said MN protein or polypeptide.
9. A recombinant nucleic acid encoding a fusion protein, that consists essentially of an MN protein or polypeptide and a non-MN protein or polypeptide, wherein the nucleotide sequence for the portion of the nucleic acid encoding the MN protein or polypeptide is selected from the group consisting of:
(a) SEQ. ID. NO.: 1;
(b) nucleotide sequences that hybridize under stringent conditions to SEQ. ID. NO.: 1 exclusive of the nucleotide sequence from 124 to 1522 or to the complement of SEQ. ID. NO.: 1 exclusive of said nucleotide sequence from 124 to 1522; and (c) degenerate variants of SEQ. ID. NO.: 1 and of the nucleotide sequences of (b);
wherein the nucleic acid encoding said MN protein or polypeptide contains at least twenty-nine nucleotides.
(a) SEQ. ID. NO.: 1;
(b) nucleotide sequences that hybridize under stringent conditions to SEQ. ID. NO.: 1 exclusive of the nucleotide sequence from 124 to 1522 or to the complement of SEQ. ID. NO.: 1 exclusive of said nucleotide sequence from 124 to 1522; and (c) degenerate variants of SEQ. ID. NO.: 1 and of the nucleotide sequences of (b);
wherein the nucleic acid encoding said MN protein or polypeptide contains at least twenty-nine nucleotides.
10. A method of detecting mutations in an isolated MN gene and/or fragment(s) thereof comprising the steps of:
amplifying one or more fragment(s) of said gene by the polymerase chain reaction (PCR); and determining whether said one or more fragments contain any mutations.
amplifying one or more fragment(s) of said gene by the polymerase chain reaction (PCR); and determining whether said one or more fragments contain any mutations.
11. An MN protein, MN fusion protein or MN polypeptide, wherein said MN protein, MN polypeptide or the MN protein portion of said MN fusion protein is encoded by a nucleic acid of at least twenty-nine nucleotides which is selected from the group consisting of:
(a) SEQ. ID. NO.: 1;
(b) nucleotide sequences that hybridize under stringent hybridization conditions to SEQ. ID. NO.: 1 exclusive of the nucleotide sequence from 124 to 1522 or to the complement of SEQ. ID. NO.: 1 exclusive of said nucleotide sequence from 124 to 1522; and (c) nucleotide sequences that differ from SEQ. ID. NO.: 1 or from the sequences of (b) in codon sequence due to the degeneracy of the genetic code.
(a) SEQ. ID. NO.: 1;
(b) nucleotide sequences that hybridize under stringent hybridization conditions to SEQ. ID. NO.: 1 exclusive of the nucleotide sequence from 124 to 1522 or to the complement of SEQ. ID. NO.: 1 exclusive of said nucleotide sequence from 124 to 1522; and (c) nucleotide sequences that differ from SEQ. ID. NO.: 1 or from the sequences of (b) in codon sequence due to the degeneracy of the genetic code.
12. An MN protein, MN fusion protein, or MN polypeptide wherein said MN protein or polypeptide has, and wherein said MN fusion protein contains, an amino acid sequence selected from the group consisting of SEQ. ID. NOS.: 2, 6, 10, 11, 13-16, 50, 51 and 53.
13. A vaccine comprising an immunogenic amount of one or more MN proteins, MN fusion proteins, and/or MN polypeptides according to Claims 11 or 12 dispersed in a physiologically acceptable, nontoxic vehicle, which amount is effective to immunize a vertebrate against a neoplastic disease associated with expression of MN antigen.
14. An antibody which specifically binds to an MN protein, an MN fusion protein and/or an MN polypeptide according to Claims 11 or 12, with the proviso that said antibody is not a monoclonal antibody designated M75 produced by a hybridoma designated VU-M75 that was deposited at the American Type Culture Collection (ATCC) in Rockville, Maryland in the United States of America under ATCC No. HB 11128.
15. A monoclonal antibody according to Claim 14 which is designated MN12 and is secreted by the hybridoma MN 12.2.2 which was deposited at the American Type Culture Collection (ATCC) in Rockville, Maryland in the United States of American under ATCC No. HB 11647.
16. An antibody according to Claim 14 which specifically binds to an MN antigen epitope selected from the group of epitopes represented by the following amino acid sequences SEQ. ID. NOS. 10-16.
17. An antibody according to Claim 14 which is linked to an imaging agent, to a chemotherapeutic agent or to a toxic agent.
18. A method of imaging pre-neoplastic or neoplastic disease in a patient comprising:
(a) injecting said patient with antibody linked to an imaging agent according to Claim 17; and (b) detecting the binding of said antibody.
(a) injecting said patient with antibody linked to an imaging agent according to Claim 17; and (b) detecting the binding of said antibody.
19. A hybridoma designated MN 12.2.2 which produces the monoclonal antibody MN12, and which was deposited at the American Type Culture Collection (ATCC) in Rockville Maryland in the United States of America under ATCC Accession No. HB 11647.
20. A method of delivering a chemotherapeutic agent or toxic agent to a cancer cell which comprises contacting said cell with an antibody linked to a chemotherapeutic agent or to a toxic agent according to Claim 17.
21. A method of treating neoplastic disease in a patient comprising administering to said patient a therapeutically effective amount of a composition comprising antibodies which specifically bind to an MN
protein, an MN fusion protein and/or an MN polypeptide according to Claims 11 or 12.
protein, an MN fusion protein and/or an MN polypeptide according to Claims 11 or 12.
22. A method of detecting and/or quantitating in a vertebrate sample MN antigen comprising the steps of:
(a) contacting said sample with one or more antibodies according to Claims 14, 15 or 16; and (b) detecting and/or quantitating binding of said antibody in said sample.
(a) contacting said sample with one or more antibodies according to Claims 14, 15 or 16; and (b) detecting and/or quantitating binding of said antibody in said sample.
23. A method according to Claim 22 wherein said vertebrate sample is a human tissue specimen, such as, a cell smear, a histological section from a biopsied tissue or organ, or an imprint preparation.
24. A method according to Claim 23 wherein said tissue specimen is ovarian, endometrial, or cervical.
25. A method of detecting and/or quantitating MN-specific antibodies in a vertebrate sample comprising the steps of:
(a) contacting and incubating the vertebrate sample with an MN protein, an MN fusion protein and/or an MN polypeptide according to Claims 11 or 12; and (b) detecting and/or quantitating binding of said MN protein, MN fusion protein and/or MN polypeptide to antibody in said sample.
(a) contacting and incubating the vertebrate sample with an MN protein, an MN fusion protein and/or an MN polypeptide according to Claims 11 or 12; and (b) detecting and/or quantitating binding of said MN protein, MN fusion protein and/or MN polypeptide to antibody in said sample.
26. A method of treating neoplastic disease and/or pre-neoplastic disease comprising inhibiting the expression of MN genes by administering one or more antisense nucleic acid sequences that hybridize under stringent conditions to mRNA transcribed from MN genes.
27. Vectors containing an MN nucleic acid sequence wherein said MN nucleic acid sequence is selected from the group consisting of:
(a) SEQ. ID. NO.:5 and its complement;
(b) nucleic acids that hybridize to SEQ. ID. NO.:5 exclusive of the nucleotide sequence from 3660 to 3951 and exclusive of the exon sequences of SEQ. ID. NOS.: 29-38, or to the complement of SEQ. ID.
NO.: 5 exclusive of said nucleotide sequence from 3660 to 3951 and exclusive of said exons of SEQ. ID. NOS.: 29-38; and (c) nucleic acids that differ from the nucleic acids of (a) or (b) due to the degeneracy of the genetic code;
wherein said nucleic acid is at least twenty-nine nucleotides in length.
(a) SEQ. ID. NO.:5 and its complement;
(b) nucleic acids that hybridize to SEQ. ID. NO.:5 exclusive of the nucleotide sequence from 3660 to 3951 and exclusive of the exon sequences of SEQ. ID. NOS.: 29-38, or to the complement of SEQ. ID.
NO.: 5 exclusive of said nucleotide sequence from 3660 to 3951 and exclusive of said exons of SEQ. ID. NOS.: 29-38; and (c) nucleic acids that differ from the nucleic acids of (a) or (b) due to the degeneracy of the genetic code;
wherein said nucleic acid is at least twenty-nine nucleotides in length.
28. Vectors containing an MN nucleic acid sequence according to Claim 27 selected from the group consisting of the plasmids A4a, XE1 and XE3 which are deposited at the American Type Culture Collection (ATCC) in Rockville, Maryland in the United States of America under the respective ATCC accession numbers 97199, 97200 and 97198.
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/260,190 | 1994-06-15 | ||
| US08/260,190 US6774117B1 (en) | 1992-03-11 | 1994-06-15 | MN gene and protein |
| US44750495A | 1995-06-07 | 1995-06-07 | |
| US08/447,504 | 1995-06-07 | ||
| US08/485,862 | 1995-06-07 | ||
| US08/481,658 US5955075A (en) | 1992-03-11 | 1995-06-07 | Method of inhibiting tumor growth using antibodies to MN protein |
| US08/486,756 US5981711A (en) | 1992-03-11 | 1995-06-07 | MN-specific antibodies and hybridomas |
| US08/485,863 US6093548A (en) | 1992-03-11 | 1995-06-07 | Detection and quantitation of MN-specific antibodies. |
| US08/485,049 US6204370B1 (en) | 1992-03-11 | 1995-06-07 | MN gene and protein |
| US08/487,077 | 1995-06-07 | ||
| US08/485,049 | 1995-06-07 | ||
| US08/487,077 US6069242A (en) | 1992-03-11 | 1995-06-07 | MN gene and protein |
| US08/485,863 | 1995-06-07 | ||
| US08/485,862 US5989838A (en) | 1992-03-11 | 1995-06-07 | Immunological methods of detecting MN proteins and MN polypeptides |
| US08/481,658 | 1995-06-07 | ||
| US08/486,756 | 1995-06-07 | ||
| PCT/US1995/007628 WO1995034650A2 (en) | 1994-06-15 | 1995-06-15 | Mn gene and protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2192678A1 true CA2192678A1 (en) | 1995-12-21 |
| CA2192678C CA2192678C (en) | 2010-12-14 |
Family
ID=27575294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2192678A Expired - Lifetime CA2192678C (en) | 1994-06-15 | 1995-06-15 | Mn gene and protein |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU2861695A (en) |
| CA (1) | CA2192678C (en) |
| WO (1) | WO1995034650A2 (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5387676A (en) * | 1992-03-11 | 1995-02-07 | Ciba Corning Diagnostics Corp. | MN gene and protein |
| US6297051B1 (en) | 1997-01-24 | 2001-10-02 | Institute Of Virology, Slovak Academy Of Sciences | MN gene and protein |
| US6297041B1 (en) | 1992-03-11 | 2001-10-02 | Institute Of Virology, Slovak Academy Of Sciences | MN gene and protein |
| JP3910798B2 (en) * | 1998-10-23 | 2007-04-25 | インスティトゥート オブ ヴァイロロジー | MN gene and protein |
| US7713704B1 (en) | 1998-10-23 | 2010-05-11 | Institute Of Virology Of The Slovak Academy Of Science | MN gene and protein |
| US20080146780A1 (en) | 1999-10-22 | 2008-06-19 | Jan Zavada | MN Gene and Protein |
| US6902890B1 (en) | 1999-11-04 | 2005-06-07 | Diadexus, Inc. | Method of diagnosing monitoring, staging, imaging and treating cancer |
| US7572891B2 (en) | 2000-02-14 | 2009-08-11 | The Regents Of The University Of California | Kidney-specific tumor vaccine directed against kidney tumor antigen G-250 |
| AR036833A1 (en) * | 2001-10-18 | 2004-10-06 | Bayer Corp | HUMAN ANTIBODIES THAT JOIN MN AND HAVE NEUTRALIZING ACTIVITY OF CELLULAR ADHESION. |
| US7910549B2 (en) | 2001-12-13 | 2011-03-22 | Institute Of Virology Of The Slovak Academy Of Sciences | MN gene and protein |
| SI3031910T1 (en) | 2002-02-21 | 2018-05-31 | Institute Of Virology Slovak Academy Of Sciences | Mn/ca ix-specific monoclonal antibodies generated from mn/ca ix-deficient mice and methods of use |
| HUE026218T2 (en) * | 2002-02-21 | 2016-05-30 | Inst Virology | MN/CA IX-specific monoclonal antibodies generated from MN/CA IX-deficient mice and methods of use |
| US8936914B2 (en) * | 2002-04-16 | 2015-01-20 | The Regents Of The University Of California | Methods of renal cell carcinoma prognosis and treatment selection with carbonic anhydrase IX |
| WO2004048544A2 (en) | 2002-11-26 | 2004-06-10 | Bayer Healthcare | Ca ix-specific inhibitors |
| JP4426621B2 (en) | 2004-05-04 | 2010-03-03 | バイエル ヘルスケア エルエルシー | Prognosis of MN / CA IX / CA9 and kidney cancer |
| EP2076611A4 (en) | 2006-10-12 | 2010-08-25 | Inst Virology | Mn/ca9 splice variants |
| US7820159B2 (en) | 2006-10-31 | 2010-10-26 | Instiute of Virology of the Slovak Academy of Sciences | MN/CA IX and EGFR pathway inhibition |
| CA2673560C (en) | 2006-12-22 | 2017-08-22 | The Regents Of The University Of California | New fusion molecule based on novel taa variant |
| US8097423B2 (en) | 2007-07-30 | 2012-01-17 | Institute Of Virology | MN/CA IX and breast cancer therapy |
| WO2014128258A1 (en) | 2013-02-22 | 2014-08-28 | Wilex Ag | Caix stratification based cancer treatment |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5387676A (en) * | 1992-03-11 | 1995-02-07 | Ciba Corning Diagnostics Corp. | MN gene and protein |
-
1995
- 1995-06-15 AU AU28616/95A patent/AU2861695A/en not_active Abandoned
- 1995-06-15 WO PCT/US1995/007628 patent/WO1995034650A2/en active IP Right Grant
- 1995-06-15 CA CA2192678A patent/CA2192678C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU2861695A (en) | 1996-01-05 |
| CA2192678C (en) | 2010-12-14 |
| MX9606402A (en) | 1998-10-31 |
| WO1995034650A3 (en) | 1996-02-15 |
| WO1995034650A2 (en) | 1995-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2192678A1 (en) | Mn gene and protein | |
| CA2182205A1 (en) | Human growth hormone | |
| JP2004512022A5 (en) | ||
| CA2225189A1 (en) | Canine factor viii gene, protein and methods of use | |
| WO2001064892A1 (en) | A NOVEL POLYPEPTIDE, A HUMAN THREONYL-tRNA SYNTHETASE 14 AND THE POLYNUCLEOTIDE ENCODING THE POLYPEPTIDE | |
| JP2002512049A (en) | Isolated nucleic acid molecules encoding cancer-associated antigens, the antigens themselves, and methods of using them | |
| CA2343979A1 (en) | Human interleukin-b50, therapeutic uses | |
| JP3091870B2 (en) | Hepatocyte cancer oncogenes | |
| US6329198B1 (en) | Production and use of human nm23 protein and antibodies therefor | |
| JP2001513755A (en) | Histidine decarboxylase assay to detect cancer | |
| JP4745583B2 (en) | Partner, manufacture and use of PTB1 domain of FEB65 | |
| EP0700446A1 (en) | Antibodies specific for dcc gene product | |
| US20030119044A1 (en) | Tumor suppressors associated with human chromosome 21q22 | |
| WO2001053495A1 (en) | Novel polypeptide--- a human iron sulphur protein 10 and polynucleotide encoding it | |
| JP2002508154A (en) | Gene family with transformation modulation activity | |
| WO2001055192A1 (en) | A novel polypeptide-human nerve growth factor 34 and the polynucleotide encoding the same | |
| MXPA01012717A (en) | Gene expression modulated in gastrointestinal inflammation. | |
| EP0979871A1 (en) | NOVEL dlg FAMILY MOLECULE, POLYNUCLEOTIDE ENCODING THE SAME, ANTIBODY AGAINST THE SAME, AND METHOD FOR DETECTING dlg GENE | |
| WO2001040487A1 (en) | Novel polypeptide---human ii aminoacyl-trna synthetase9 and polynucleotide encoding it | |
| JP2002541842A (en) | Nucleic acids encoding novel truncated CART proteins corresponding to truncated CART polypeptides and their use for therapeutic and diagnostic purposes | |
| JPH08294391A (en) | Fused protein of dihydrofolic acid reductase-antigen polypeptide of chlamydia pneumoniae, dna coding for the same, recombinant vector containing the same dna, transformer containing the same recombinant vector and production of anti-chlamydia pneumoniae antibody | |
| WO2001071003A1 (en) | A novel polypeptide, a human serine protease 8 and the polynucleotide encoding the polypeptide | |
| WO2001055406A1 (en) | A novel polypeptide-dna polymerase iii 18 and the polynucleotide encoding said polypeptide | |
| WO2001090170A1 (en) | A novel polypeptide, a human neural cell adhesion protein 31 and the polynucleotide encoding the polypeptide | |
| WO2001055381A1 (en) | A novel polypeptide, a human transcription regulatory factor 80 and the polynucleotide encoding the polypeptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20150615 |